Literature DB >> 21958951

Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.

Juyang Kim1, Wongyoung Kim, Hyun J Kim, Sohye Park, Hyun-A Kim, Daehee Jung, Hye-Jung Choi, Sang J Park, Robert S Mittler, Hong R Cho, Byungsuk Kwon.   

Abstract

CD25(+)CD4(+)Foxp3(+) regulatory T cells (Tregs) play a pivotal role in the maintenance of self-tolerance and regulation of immune responses. Previous studies have demonstrated that CD137 signals can promote proliferation and survival of Tregs in vitro. Here, we show that in vivo CD137-induced expansion of Tregs in naive mice was dependent upon IL-2 secreted by memory T cells. Tregs primed by anti-CD137 mAbs had a higher immunosuppressive capacity. Preconditioning with anti-CD137 mAbs significantly inhibited graft-versus-host disease (GVHD) in the C57BL/6 → (C57BL/6 × DBA/2) F1 acute GVHD model. In this disease model, a high proportion of host Tregs remained long-term in the recipient spleen, whereas donor hematopoietic cells replaced other host bone marrow-derived cells. Transient depletion of Tregs before transfer of donor cells completely abrogated the inhibitory effect of anti-CD137 mAbs on GVHD. In addition, adoptive transfer of anti-CD137-primed Tregs ameliorated GVHD. Our results demonstrate that it is possible to enhance the survival and/or the immunosuppressive activity of host Tregs in nonmyeloablative GVHD, and that 1 way of accomplishing this is through the prophylactic use of anti-CD137 mAbs in nonmyeloablative GVHD.
Copyright © 2012 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958951     DOI: 10.1016/j.bbmt.2011.09.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.

Authors:  Norifumi Sawamukai; Atsushi Satake; Amanda M Schmidt; Ian T Lamborn; Priti Ojha; Yoshiya Tanaka; Taku Kambayashi
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

Review 2.  Reverse signaling through the co-stimulatory ligand, CD137L, as a critical mediator of sterile inflammation.

Authors:  Sang Jun Park; Hye Jeong Kim; Jong Soo Lee; Hong Rae Cho; Byungsuk Kwon
Journal:  Mol Cells       Date:  2012-04-20       Impact factor: 5.034

Review 3.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

Review 4.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.

Authors:  Ido Somekh; Marini Thian; David Medgyesi; Nesrin Gülez; Thomas Magg; Alejandro Gallón Duque; Tali Stauber; Atar Lev; Ferah Genel; Ekrem Unal; Amos J Simon; Yu Nee Lee; Artem Kalinichenko; Jasmin Dmytrus; Michael J Kraakman; Ginette Schiby; Meino Rohlfs; Jeffrey M Jacobson; Erdener Özer; Ömer Akcal; Raffaele Conca; Türkan Patiroglu; Musa Karakukcu; Alper Ozcan; Tala Shahin; Eliana Appella; Megumi Tatematsu; Catalina Martinez-Jaramillo; Ivan K Chinn; Jordan S Orange; Claudia Milena Trujillo-Vargas; José Luis Franco; Fabian Hauck; Raz Somech; Christoph Klein; Kaan Boztug
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

Review 6.  Antibody- and aptamer-strategies for GvHD prevention.

Authors:  Christopher Oelkrug; Ulrich Sack; Andreas Boldt; Isis C Nascimento; Henning Ulrich; Stephan Fricke
Journal:  J Cell Mol Med       Date:  2014-10-29       Impact factor: 5.310

7.  CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures.

Authors:  Anna Nowak; Dominik Lock; Petra Bacher; Thordis Hohnstein; Katrin Vogt; Judith Gottfreund; Pascal Giehr; Julia K Polansky; Birgit Sawitzki; Andrew Kaiser; Jörn Walter; Alexander Scheffold
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

Review 8.  The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation.

Authors:  Sabrina Copsel; Dietlinde Wolf; Krishna V Komanduri; Robert B Levy
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

9.  Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand.

Authors:  Byungsuk Kwon
Journal:  Immune Netw       Date:  2012-10-31       Impact factor: 6.303

10.  Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Dali Cheng; Zhijun Xia; Meng Luan; Liangliang Wu; Gang Wang; Shulan Zhang
Journal:  J Transl Med       Date:  2013-09-17       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.